GSK vs Viatris
GSK and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GSK and VTRS compare
Viatris grew revenue faster over the last twelve months (4.4% versus 4.1% for GSK).
Viatris pays a dividend yielding 2.5%; GSK does not pay one.
GSK scores higher on the StockData Score (9 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GSK | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | – | $21.9B |
| Share price | $49.51 | $19.04 |
| Change, 1 year | 7.8% | 85.3% |
| Change, 5 years | −7.1% | 38.6% |
| Beta (5Y) | 0.26 | 0.87 |
| Employees | 500K | 30K |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/S | – | 1.5× |
| EV/EBITDA | – | 12.6× |
| P/FCF | – | 11.2× |
| FCF yield | – | 8.9% |
| Fair value | – | $20.87 |
| Margin of safety | – | 8.8% |
| Growth | ||
| Revenue growth (TTM) | 4.1% | 4.4% (better) |
| Revenue growth, 5Y average | 6.0% (better) | 3.7% |
| Net income growth (TTM) | 122% | – |
| EPS growth (TTM) | 123% | – |
| EPS growth, 5Y average | −0.54% | – |
| Profitability | ||
| Gross margin | 72.4% (better) | 34.8% |
| Operating margin | 24.3% (better) | −0.59% |
| Net margin | 17.5% | – |
| FCF margin | 19.6% (better) | 13.3% |
| Return on equity | 38.0% | – |
| Return on invested capital | 23.4% | – |
| Financial health | ||
| Debt / equity | 1.08 | – |
| Net debt / EBITDA | 1.40 (better) | 4.59 |
| Interest coverage | 11.3× (better) | −0.2× |
| Current ratio | 0.82 | 1.58 (better) |
| Altman Z-score | – | 1.16 |
| Piotroski F-score | 9 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.5% |
| Payout ratio | 44.9% | – |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.9% |
| Ownership | ||
| Held by institutions | 8.0% | 91.5% |
| Held by insiders | 0.05% | 0.36% |
| Insider net buying, 12 months | – | −$1.1M |
| Superinvestors holding | 1 | 3 (better) |
| Short interest, % of float | – | 3.7% |
Go deeper
- GSK stock overview
- GSK income statement
- GSK valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.